Emerging treatments
Anifrolumab
Anifrolumab is a type 1 interferon receptor antagonist. Two cases of severe and refractory DLE showed improvement when treated with anifrolumab.[36] However, further evidence is needed to determine the safety and efficacy of this drug in treating DLE.
Litifilimab
Litifilimab is a humanised monoclonal antibody that binds to blood dendritic cell antigen 2 (BDCA2). Treatment with litifilimab was superior to placebo in a phase 2 trial involving patients with CLE.[37] However, further evidence is needed to determine the safety and efficacy of this drug in treating DLE.
Use of this content is subject to our disclaimer